PC
BIO icon

Passport Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Passport Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,652
Closed -$596K – 200
2014
Q1 		$596K Buy
+4,652
New +$596K 0.02% 111

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Passport Capital's BIO Position: Q2 2014 in Review

Passport Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2014, closing a stake of 4,652 shares — an estimated $596K sold.

Passport Capital first reported a position in BIO in Q1 2014 and held it in 1 quarter. The position peaked at $596K in Q1 2014. 204 funds tracked by Wall St. Rank hold BIO as of Q2 2014.

  • Passport Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2014 after selling out during the quarter.
  • Passport Capital sold 4,652 Bio-Rad Laboratories Class A shares in Q2 2014, an estimated $596K.
  • Passport Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 1 quarter.
  • Passport Capital's Bio-Rad Laboratories Class A position peaked at $596K in Q1 2014.
  • 204 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2014.

Based on Passport Capital's 13F filing for Q2 2014, filed 14 Aug 2014.